Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Different Significance of Reactogenicity in Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms: BNT162b2 mRNA Versus ChAdOx1 nCoV19 Vaccine

NCT05315856 is registered in ClinicalTrials.gov with Korea University Guro Hospital as lead sponsor.

NCT NCT05315856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05315856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Different Significance of Reactogenicity in Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms: BNT162b2 mRNA Versus ChAdOx1 nCoV19 Vaccine
Lead sponsor
Korea University Guro Hospital
Phase
Observational
Overall status
Unknown status
Start date
March 1, 2021
Completion date
December 31, 2022
Enrollment
120 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 vaccination, inflammation, vaccine adverse reaction, vaccine immune response